Medigen Vaccine Biologics Cash Flow Conversion Efficiency

Latest as of June 2026: -0.026x

Medigen Vaccine Biologics cash flow conversion efficiency. Based on the latest financial reports, Medigen Vaccine Biologics (6547) has a cash flow conversion efficiency ratio of -0.026x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-91.20 Million ≈ $-2.87 Million USD) by net assets (NT$3.56 Billion ≈ $112.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Medigen Vaccine Biologics (2012–2025)

Cash flow conversion efficiency of Medigen Vaccine Biologics from 2012 to 2025. This chart illustrates how Medigen Vaccine Biologics's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 6547 stock price for real-time trading data and today's change.

Medigen Vaccine Biologics Cash Flow Conversion Ratio Explained

Medigen Vaccine Biologics cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Medigen Vaccine Biologics Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Medigen Vaccine Biologics ranked by their cash flow conversion efficiency. Also see market cap of Medigen Vaccine Biologics for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Keck Seng Malaysia Bhd
KLSE:3476
0.010x
Jinxiandai Information Industry Co
SHE:300830
0.013x
Salmones Camanchaca S.A
SN:SALMOCAM
-0.019x
Community Healthcare Trust Inc
NYSE:CHCT
0.042x
Energisa Mato Grosso - Distribuidora de Energia S/A
SA:ENMT3
-0.074x
Caleres Inc
NYSE:CAL
0.123x
High Liner Foods Incorporated
TO:HLF
-0.007x
Chongqing Yukaifa Co Ltd
SHE:000514
0.003x

Annual Cash Flow Conversion Efficiency for Medigen Vaccine Biologics (2012–2025)

The table below shows the annual cash flow conversion efficiency of Medigen Vaccine Biologics from 2012 to 2025. Review 6547 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 NT$3.48 Billion
≈ $109.62 Million
NT$-49.09 Million
≈ $-1.55 Million
-0.014x -233.28%
2024-12-31 NT$3.85 Billion
≈ $121.30 Million
NT$40.75 Million
≈ $1.28 Million
0.011x +108.52%
2023-12-31 NT$3.85 Billion
≈ $121.19 Million
NT$-477.75 Million
≈ $-15.05 Million
-0.124x +43.27%
2022-12-31 NT$5.03 Billion
≈ $158.44 Million
NT$-1.10 Billion
≈ $-34.69 Million
-0.219x -276.53%
2021-12-31 NT$4.68 Billion
≈ $147.32 Million
NT$579.89 Million
≈ $18.27 Million
0.124x +166.03%
2020-12-31 NT$3.14 Billion
≈ $98.97 Million
NT$-589.97 Million
≈ $-18.59 Million
-0.188x +44.52%
2019-12-31 NT$1.37 Billion
≈ $43.06 Million
NT$-462.65 Million
≈ $-14.58 Million
-0.338x -53.14%
2018-12-31 NT$1.61 Billion
≈ $50.79 Million
NT$-356.33 Million
≈ $-11.23 Million
-0.221x -54.92%
2017-12-31 NT$1.52 Billion
≈ $47.92 Million
NT$-217.03 Million
≈ $-6.84 Million
-0.143x -28.34%
2016-12-31 NT$1.47 Billion
≈ $46.30 Million
NT$-163.37 Million
≈ $-5.15 Million
-0.111x -169.10%
2015-12-31 NT$1.34 Billion
≈ $42.35 Million
NT$216.26 Million
≈ $6.81 Million
0.161x +133.76%
2014-12-31 NT$1.08 Billion
≈ $33.99 Million
NT$-513.98 Million
≈ $-16.19 Million
-0.476x -201.54%
2013-12-31 NT$457.94 Million
≈ $14.43 Million
NT$-72.36 Million
≈ $-2.28 Million
-0.158x -269.62%
2012-12-31 NT$128.00 Million
≈ $4.03 Million
NT$-5.47 Million
≈ $-172.40K
-0.043x --

About Medigen Vaccine Biologics

TWO:6547 Taiwan Biotechnology
Market Cap
$407.56 Million
NT$12.94 Billion TWD
Market Cap Rank
#12600 Global
#435 in Taiwan
Share Price
NT$39.35
Change (1 day)
-7.08%
52-Week Range
NT$35.50 - NT$68.10
All Time High
NT$280.20
About

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more